Thalidomide- and lenalidomide-associated thromboembolism

Community Oncology

Volumn 4, Issue 3, 2007, Pages 147-148

  Angelotta, Cara ^a   Bennett, Charles L ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; THALIDOMIDE; WARFARIN;

ANEMIA; ASTHENIA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONFUSION; CONSTIPATION; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG INFORMATION; DYSPNEA; EDEMA; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOCALCEMIA; INSOMNIA; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; RASH; SENSORY NEUROPATHY; VENOUS THROMBOEMBOLISM;

EID: 34147105989     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1548-5315(11)70074-2     Document Type: Conference Paper

References (5)

1. Thalidomide [package insert]. Food and Drug Administration website. Available at: www.fda.gov/cder/foi/label/2006/021430s000,020785s0311bl.pdf. Accessed September 6, 2006.
2. Lenalidomide [package insert]. Food and Drug Administration website. Available at: www.fda.gov/cder/foi/label/2006/021880s001.pdf. Accessed September 6, 2006.
3. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Raisch DW, Richardson PR. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006;296:2558-2560.
4. Blumenthal R. Require Celgene Corporation to revise the labeling of Thalomid capsules to strengthen warnings of the potential for serious adverse events. Vol 2006: US Food and Drug Administration Web site; 2005.
5. Galson S. Letter to Richard Blumenthal, Connecticut Attorney General. Available at: www.ct.gov/ag/lib/ag/departments/ thalomid_citizens_petition_response.pdf. Accessed June 26, 2006.